Ovid Therapeutics, Inc.
http://www.ovidrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ovid Therapeutics, Inc.
Stoke’s Persistence Pays Off With Dravet Syndrome Therapy
Results showing a 74% reduction in seizures set up Stoke for a pivotal study and could make STK-001 the first disease-modifying agent for the condition.
Takeda Charges Into Diversification With ITP Win
The company announced positive topline results from a Phase II study of mezagitamab and expects to have five programs in Phase III development this fiscal year.
Bespoke Gene Therapy ‘Playbook’ Outlines Platform Approach To AAV-Based Treatments
Supporting ‘n of 1’ gene therapy development, the playbook from a Foundation for the National Institutes of Health-backed consortium aims to help investigators who are not traditional product sponsors prepare for meetings with US FDA and IND submissions.
Stark Warnings For Pharma On Preserving Trust And Overcoming Risk Aversion
Industry veteran Jeremy Levin, the 2023 winner of the Scrip Awards Lifetime Achievement Award, speaks to In Vivo about what holds back innovation in the biopharma industry, new technologies and commitments needed to protect the future relationship between drug developers and patients.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice